Targeting Glioblastoma: Efficacy of Ruthenium-Based Drugs
Date Issued
2024
Author(s)
Rasin
P Surendran
SS Karthik
KS Haribabu
J Sreekanth
DOI
10.1021/acs.chemrestox.4c00188
Abstract
Ruthenium compounds offer improved selectivity and fewer side effects compared to platinum-based drugs in glioblastoma treatment. Insights into their interactions with transferrin suggest targeted drug delivery, while photoactivated chemotherapy is a novel cytotoxic approach in tumor tissues. C1 [Rasin, Puthiyavalappil] Chennai Inst Technol CIT, Ctr Nonlinear Syst, Chennai 600069, India. [Surendran, Sravan Sangeeth; Karthik, K. S.; Sreekanth, Anandaram] Natl Inst Technol, Dept Chem, Tiruchirappalli 620015, Tamil Nadu, India. [Haribabu, Jebiti] Univ Atacama, Fac Med, ATACAMA OMICS, Copiapo 1532502, Chile. C3 National Institute of Technology (NIT System); National Institute of Technology Tiruchirappalli; Universidad de Atacama


